Sandoz has an unwavering commitment to increasing patient access to high-quality, life-enhancing biosimilars. Sandoz is the global market leader and currently markets three biosimilars outside the US, each of which occupies the #1 biosimilar position in its respective category. Sandoz has a leading pipeline with several biosimilars across the various stages of development, including five programs in Phase III clinical trials/filing preparation.


FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

September 28, 2015

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the FDA has accepted its Biologics License Application (BLA) for its proposed biosimilar to Amgen’s US-licensed Enbrel® (etanercept).


Biosimilars: The Sandoz Way
Joerg Windisch talks about biosimilars development and manufacturing at Sandoz.

Watch the video

Biosimilar medicines offer physicians more choices at affordable prices thereby increasing patient access without increasing overall spending.

Read more

Bending the curve of rising healthcare costs without compromising access to quality medical care for its citizens remains one of the most daunting challenges that governments are faced with.

Read more